BGP-15, a hydroximic acid derivative, protects against cisplatin- or taxol-induced peripheral neuropathy in rats.
The neuroprotective effect of BGP-15 against peripheral sensory neuropathy was studied in rats that were exposed to short-term cisplatin or taxol administration. The changes of nerve conduction velocity were determined in situ after treating the Wistar rats with BGP-15 (50, 100, and 200 mg/kg po daily doses throughout the experiment), cisplatin (1.5 mg/kg ip daily dose for 5 days), or taxol (5.0 mg/kg ip daily dose every other day in a 10-day interval) alone or giving the test compound in combination with cisplatin or taxol. Electrophysiological recordings were carried out in vivo by stimulating the sciatic nerve at both sciatic notch and ankle site. Neither motor nor sensory nerve conduction velocity was altered by any dose level of BGP-15 tested. Both anticancer drugs decreased the sensory nerve conduction velocity (SNCV). BGP-15 treatment prevented the impairment of SNCV either in part or totally in the cisplatin- or taxol-treated groups. This neuroprotective potential of BGP-15 could be well correlated with its recently described poly(ADP-ribose) polymerase- inhibitory effect and its ability to protect against the damages induced by the increased level of reactive oxygen species in response to anticancer treatment.
Bárdos
G
G
Department of Physiology and Neurobiology, Eötvös Loránd University, Budapest, Hungary. bardosgy@ludens.elte.hu
Móricz
K
K
Jaszlits
L
L
Rabloczky
G
G
Tory
K
K
Rácz
I
I
Bernáth
S
S
Sümegi
B
B
Farkas
B
B
Literáti-Nagy
B
B
Literáti-Nagy
P
P
D000818:Animals; D000970:Antineoplastic Agents / Q000037:antagonists & inhibitors* / Q000633:toxicity*; D000972:Antineoplastic Agents, Phytogenic / Q000037:antagonists & inhibitors* / Q000633:toxicity*; D001835:Body Weight / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D002945:Cisplatin / Q000037:antagonists & inhibitors* / Q000633:toxicity*; D004594:Electrophysiology; D008297:Male; D009046:Motor Neurons / Q000187:drug effects; D009431:Neural Conduction / Q000187:drug effects; D009475:Neurons, Afferent / Q000187:drug effects; D010091:Oximes / Q000494:pharmacology*; D017239:Paclitaxel / Q000037:antagonists & inhibitors* / Q000633:toxicity*; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced / Q000517:prevention & control*; D010880:Piperidines / Q000494:pharmacology*; D051381:Rats
D000970:Antineoplastic Agents; D000972:Antineoplastic Agents, Phytogenic; D010091:Oximes; D010880:Piperidines; D017239:Paclitaxel; D002945:Cisplatin; C405586:BGP 15